Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Deals

Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio

Fineline Cube Mar 3, 2025

Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...

Drug

CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment

Fineline Cube Mar 3, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...

Company Deals

Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion

Fineline Cube Mar 3, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure,...

Company Deals

Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs

Fineline Cube Mar 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...

Company

AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis

Fineline Cube Mar 2, 2025

The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical...

Company

Biointron Biologics Files for Public Offering, Aims for BSE Listing

Fineline Cube Mar 2, 2025

On February 11, Biointron Biologics released its tutoring filing report for the public offering of...

Company

Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan

Fineline Cube Mar 1, 2025

On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed...

Company

BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success

Fineline Cube Feb 28, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...

Company

Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction

Fineline Cube Feb 28, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024...

Company

Viatris Q4 and Full-Year Results Show Greater China Growth

Fineline Cube Feb 28, 2025

US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In...

Company Deals

SciClone Pharmaceuticals Licenses Eisai’s Tasurgratinib for China

Fineline Cube Feb 28, 2025

China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing...

Company Drug

Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study

Fineline Cube Feb 28, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...

Company Deals

Sino Biopharmaceutical and Sciwind Biosciences Partner on CPX102 Development

Fineline Cube Feb 28, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences...

Company Drug

Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy

Fineline Cube Feb 28, 2025

German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...

Company Drug

Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study

Fineline Cube Feb 28, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study

Fineline Cube Feb 28, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration...

Company

GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor

Fineline Cube Feb 28, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...

Company Medical Device

Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study

Fineline Cube Feb 28, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...

Company Drug

Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study

Fineline Cube Feb 28, 2025

China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase...

Company Drug

CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT

Fineline Cube Feb 28, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...

Posts pagination

1 … 200 201 202 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.